FAScinate Therapeutics
Pre-clinicalPatients diagnosed with Parkinson’s disease are faced with a difficult truth: there’s nothing they can do to keep their condition from worsening. KM-819 changes that—slowing and even stopping the progression of neurodegenerative conditions like PD and multiple system atrophy.
Founded
2018
Focus
Small Molecules
About
Patients diagnosed with Parkinson’s disease are faced with a difficult truth: there’s nothing they can do to keep their condition from worsening. KM-819 changes that—slowing and even stopping the progression of neurodegenerative conditions like PD and multiple system atrophy.
Funding History
3Total raised: $82.5M
Series A$65MMPM CapitalSep 15, 2023
Seed$5.5MUndisclosedJun 15, 2022
Seed$12MMPM CapitalMar 15, 2022
Company Info
TypePrivate
Founded2018
LocationCambridge, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile